Evidence That Eukaryotic Translation Elongation Factor 1A (eEF1A) Binds the Gcn2 Protein C Terminus and Inhibits Gcn2 Activity**

Received for publication, April 15, 2011, and in revised form, August 3, 2011 Published, JBC Papers in Press, August 17, 2011, DOI 10.1074/jbc.M111.248898

Jyothsna Visweswaraiah §1, Sebastien Lageix §, Beatriz A. Castilho §, Lara Izotova §, Terri Goss Kinzy §, Alan G. Hinnebusch §, and Evelyn Sattlegger §‡

From the §Institute of Natural Sciences, Massey University, Auckland 0745, New Zealand, the §Laboratory of Gene Regulation and Development, NICHD, National Institutes of Health, Bethesda, Maryland 20892, the ‡Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo, São Paulo SP 04023-062, Brazil, and the §Department of Molecular Genetics, Microbiology and Immunology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08854-5635

The eukaryotic elongation factor 1A (eEF1A) delivers aminoacyl-tRNAs to the ribosomal A-site during protein synthesis. To ensure a continuous supply of amino acids, cells harbor the kinase Gcn2 and its effector protein Gcn1. The ultimate signal for amino acid shortage is uncharged tRNAs. We have proposed a model for sensing starvation, in which Gcn1 and Gcn2 are tethered to the ribosome, and Gcn1 is directly involved in delivering uncharged tRNAs from the A-site to Gcn2 for its subsequent activation. Gcn1 and Gcn2 are large proteins, and these proteins as well as eEF1A access the A-site, leading us to investigate whether there is a functional or physical link between these proteins. Using Saccharomyces cerevisiae cells expressing His₆-eEF1A and affinity purification, we found that eEF1A co-eluted with Gcn2. Furthermore, Gcn2 co-immunoprecipitated with eEF1A, suggesting that they reside in the same complex. The purified GST-tagged Gcn2 C-terminal domain (CTD) was sufficient for precipitating eEF1A from whole cell extracts generated from gcn2Δ cells, independently of ribosomes. Purified GST-Gcn2-CTD and purified His₆-eEF1A interacted with each other, and this was largely independent of the Lys residues in Gcn2-CTD known to be required for tRNA binding and ribosome association. Interestingly, Gcn2-eEF1A interaction was diminished in amino acid-starved cells and by uncharged tRNAs in vitro, suggestive of eEF1A functions as a Gcn2 inhibitor. Consistent with this possibility, purified eEF1A reduced the ability of Gcn2 to phosphorylate its substrate, elf2α, but did not diminish Gcn2 autophosphorylation. These findings implicate eEF1A in the intricate regulation of Gcn2 and amino acid homeostasis.

In all living organisms, proteins are synthesized on the ribosome by the sequential addition of amino acids to the growing peptide chain. During this process, soluble factors must cycle on and off the ribosome in an orderly fashion. One such factor, the eukaryotic translation elongation factor 1A (eEF1A), delivers the aminoacylated tRNA (aa-tRNA)³ to the ribosomal acceptor site (A-site) in a codon-specific manner (1). After aa-tRNA delivery, eEF1A is released in its GDP-bound form and must be recycled to its GTP-bound form. Following addition of the amino acid to the growing polypeptide chain, the deacylated tRNA is ultimately released from the ribosomal exit (E) site and must be recharged with the appropriate amino acid to be delivered again to the ribosomal A-site by eEF1A.

Constant protein synthesis is essential to life and along with this a steady supply of amino acids. Therefore, to immediately counteract any potential amino acid shortages, it is paramount to constantly monitor amino acid availability. In eukaryotes, this is accomplished by a highly conserved signal transduction pathway called general amino acid control (GAAC) in fungi (2). One key component in this signal transduction pathway is a protein kinase that detects amino acid starvation, called Gcn2 in yeast and mammals (2), and cpc-3 or CpcC in filamentous fungi (3, 4).

Under amino acid starvation, the cellular level of uncharged tRNAs increases (2). These are detected by Gcn2, with the aid of its effector proteins Gcn1 and Gcn20. The Gcn2 kinase activity then becomes stimulated and phosphorylates Ser-51 in the α subunit of eukaryotic translation initiation factor 2 (eIF2). eIF2 is essential for delivering Met-tRNA⁺Met to the ribosomal P-site during translation initiation. eIF2α phosphorylation by Gcn2 reduces eIF2 function, thereby leading to reduced global protein synthesis and thus reduced consumption of amino acids. At the same time, eIF2α phosphorylation leads to increased translation of mRNAs containing specific upstream open reading frames. These mRNAs encode for transcriptional activators, Gcn4 in yeast, cpc-1 or CpcA in filamentous fungi, and ATF4 in mammals (2, 5), that up-regulate the transcription of stress-related genes, including amino acid biosynthetic genes. Thus,

* This work was supported, in whole or in part, by National Institutes of Health Intramural Research Program (to A. G. H.) and by Grant R01 GM57483 (to T. G. K.). This work was also supported by a grant from Fundação de Apoio à Pesquisa no Estado de São Paulo (to B. A. C.), The Marsden Fund Council from Government funding, administered by the Royal Society of New Zealand (MAU0607), and a Massey University Technician Award and Research Fund (to E. S.).

† This article was selected as a Paper of the Week.

‡ Supported by a Massey University Ph.D. scholarship.

§1 To whom correspondence should be addressed: Institute of Natural Sciences, Massey University, P. O. Box 102 904, North Shore Mail Centre, Auckland, Albany 0745, New Zealand. Tel.: 64-9-414-0800 (Ext. 9665); Fax: 64-9-441-8142; E-mail: e.sattlegger@massey.ac.nz.

3 The abbreviations used are: aa-tRNA, aminoacyl tRNA; GAAC, general amino acid control; WCE, whole cell extract; CTD, C-terminal domain; PRS, postribosomal supernatant.
increased expression levels of these transcriptional activators lead to increased amino acid biosynthesis.

The exact mechanism of how Gcn2 detects the starvation signal is poorly understood as is the exact function of its effector proteins Gcn1 and Gcn20. Gcn2 is composed of several domains (2). The N-terminal RWD domain directly contacts proteins Gcn1 and Gcn20. Gcn2 is composed of several domains (2). The N-terminal RWD domain directly contacts proteins Gcn1 and Gcn20. Gcn2 is composed of several domains (2).

Our current working model, we propose that uncharged tRNAs are transferred to Gcn2 within this complex. In our current working model, we propose that uncharged tRNAs are transferred to Gcn2 within this complex. In current working model, we propose that uncharged tRNAs are transferred to Gcn2 within this complex. In current working model, we propose that uncharged tRNAs are transferred to Gcn2 within this complex. In current working model, we propose that uncharged tRNAs are transferred to Gcn2 within this complex.

### TABLE 1
Strains used in this study

| Genetic background, H1511 | Genotype | Source |
|--------------------------|----------|--------|
| H1511                    | MATa ura3-52 trp1-63 leu2-3,112 GAL2* | Ref. 41 |
| H2557                    | MATa ura3-52 trp1-63 leu2-3,112 GAL2* gcn2Δ | C. R. Vazquez de Aldana and A. G. Hinnebusch |

### TABLE 2
Plasmids used in this study

| Plasmid          | Gene* | Vector | Source |
|------------------|-------|--------|--------|
| pB131            | GST⁵⁶ gcn2(1–272), here designated GST-gcn2-NTD | pGEX-5x-1 | Ref. 21 |
| pHO551           | GST⁵⁶-gcn2(568–998), here designated GST-gcn2-PK | pGEX-5x-1 | Ref. 42 |
| pHO530           | GST⁵⁶-gcn2(970–1497), here designated GST-gcn2-His⁶RS | pGEX-5x-1 | Ref. 41 |
| pHQ531           | GST⁵⁶-gcn2(1498–1659), here designated GST-gcn2-CTD | pGEX-5x-1 | Ref. 42 |
| pIV02            | GST⁵⁶-gcn2(1498–1659)-K1552L, K1553L, K1556L, here designated GST-gcn2-CTD | pGEX-5x-1 | This study |
| pSL101           | FLAG²–TEV–Gcn2, under galactose-inducible promoter | pEMBLyex4 | This study |

* Numbers in parentheses indicate amino acids encoded by the respective gene.

** This is the recognition site for the tobacco etch virus (TEV) protease.

### EXPERIMENTAL PROCEDURES

**Strains and Plasmids—** Yeast strains and plasmids used in this study are summarized in Tables 1 and 2, respectively. Details of their construction are as follows.

ESY10101, a gcn2Δ strain harboring plasmid borne His⁶-eEF1A as the only version of eEF1A, was generated by transformation of TKY865 with EcoRI- and XbaI-digested plasmid.
pHQ1093, containing the gcn2Δ::hisG::URA3::hisG disruption cassette (11). Eviction of the URA3 marker was monitored by growth on 5-fluoroorotic acid medium, and deletion of GCN2 was verified by complementation tests with plasmid-borne Gcn2.

pJV02 harboring GST-tagged Gcn2-CTD with K1552L, K1553L, and K1556L substitutions was generated by PCR amplifying Gcn2 nucleotides 5620–6013 using primers ES2018 and ES2019 and plasmid pDH111 as template (8). The PCR fragment was digested with BglII and cloned into the similarly digested vector pHQ531. The resulting plasmid was sequence-verified.

pSL101 harboring FLAG-tobacco etch virus protease site-tagged Gcn2 under a galactose-inducible promoter was constructed by replacing in plasmid pHQ1589 (harboring Gcn2 with N-terminal FLAG and tobacco etch virus protease site and C-terminal His6 tag) the BspEl-PstI fragment by the BspEl-PstI fragment from plasmid pH103 (8).

**Protein Purification**—A C-terminally truncated version of yeast eIF2α was purified from *Escherichia coli*, and FLAG-tagged Gcn2 was purified from yeast as described previously except that Gcn2 was eluted by adding tobacco etch virus protease (Invitrogen) (8, 12).

For eEF1A-Gcn2 interaction assays and *in vitro* Gcn2 kinase assays, His6-tagged eEF1A was purified from gcn2Δ strain ESY10101 grown in 300 ml ofYPD liquid medium to exponential phase at around A600 = 2. Whole cell extract was generated by vortexing the cell pellet with equal volumes of glass beads and an equal volume of breaking buffer containing 30 mM HEPES, pH 7.4, 500 mM NaCl, 1 tablet of EDTA free protease inhibitors (Roche Applied Science) per 25 ml, 5 mM β-mercaptoethanol, 1 μg/ml pepstatin, and 1 mM PMSF as published elsewhere (13). After centrifugation at 10,000 rpm for 10 min at 4 °C, the supernatant was incubated with iMAC resin (Bio-Rad) for 1 h at 4 °C with gentle agitation, washed with breaking buffer, and eluted with breaking buffer containing 250 mM imidazole.

For *in vitro* Gcn2 kinase assays, untagged endogenous *Saccharomyces cerevisiae* eEF1A was purified as described in Ref. 14.

**Protein Interaction Assays**—Co-immunoprecipitation assays were performed as described previously (6) using rabbit polyclonal antibodies against yeast eEF1A (15).

For eEF1A binding and stepwise elution assays, whole cell extract was generated as published earlier (13) using a buffer containing 30 mM HEPES, pH 7.4, 50 mM KCl, 10% glycerol, 1 complete tablet without EDTA (Roche Applied Science) per 25 ml of buffer, 5 mM β-mercaptoethanol, 5 mM imidazole, pH 7, and 1 mM PMSF. 3 mg of total protein in 400 μl of buffer was incubated with Sepharose beads for 30 min at 4 °C and spun for 1 min at 10,000 rpm at 4 °C. The supernatant was then added to Ni2+-charged iMAC resin (Bio-Rad). After incubation for 1 h at 4 °C, the resin was subjected to stepwise elutions by using buffer with increasing imidazole concentrations (ranging from 10 to 250 mM imidazole).

In *in vitro* binding assays using GST fusion proteins were performed by expressing GST-tagged proteins in *E. coli* BL21. Whole cell extract was generated using the breaking buffer from the co-immunoprecipitation assay but 10% glycerol was added. Immediately after harvesting, *E. coli* cells were incubated in breaking buffer and 1 mg/ml lysozyme for 1 h at 4 °C and then frozen. The next day cells were thawed in an ice water mixture and incubated at 4 °C until the sample gained high viscosity. This is a sign of efficient breakage due to large amounts of genomic DNA being released from the cells. Then DNase (5 μg/ml final concentration) and RNase (10 μg/ml final concentration) were added, and the sample was incubated further until the viscosity was lost. Samples were spun for 20 min at 12,000 rpm at 4 °C. The supernatant was aliquoted and frozen. Aliquots of this extract were incubated with glutathione-linked Sepharose, and unbound proteins were washed off. Whole cell extract was generated from the gcn2Δ strain H2557 as published elsewhere (13). If ribosomes needed to be removed, a postribosomal supernatant (PRS) was generated by subjecting the WCE to 200,000 × g (~68,000 rpm, TL-100 ultracentrifuge, rotor TLA-100, Beckman) for 1 h at 4 °C. Then the WCE or PRS, or purified eEF1A, was added to the glutathione resin-bound GST fusion protein and incubated for 1 h at 4 °C. Unbound proteins were washed off, and the precipitates were subjected to SDS-PAGE and immunoblotting using antibodies as indicated in the respective figures. If necessary, RNA was removed from protein samples prior to conducting the interaction assays by adding 125 μg of RNase A per 15 A260 units to the sample followed by an incubation for 15 min at 4 °C.

**Gcn2 Activity Assay**—1 pmol of Gcn2 was incubated with eEF1A for 30 min at 30 °C in kinase buffer (20 mM Tris-HCl, pH 8, at 30 °C, 10 mM MgCl2, 50 mM NaCl, 1 mM DTT, 100 μM PMSF, 25 ng/μl BSA). Then 30 pmol of eIF2α and 100 or 200 pmol of [γ-32P]ATP were added (total final volume 20 μl), and the samples were incubated for a further 20 min. The reaction was stopped by adding 2× Laemmli protein loading buffer. The samples were subjected to SDS-PAGE, and the gel was then stained with Coomassie dye (GelCode Blue Stain Reagent, Thermo Scientific) and exposed to a Phosphor Screen. The intensity of bands was quantified using the Molecular Dynamics STORM 840 phosphorimager and ImageQuant software. The gel was then vacuum-dried and the Coomassie staining documented.

**Protein Electrophoresis and Immunoblotting Techniques**—Proteins were separated by SDS-PAGE using 4–12% gradient gels. Proteins were visualized in gels by staining with Coomassie dye (GelCode Blue Stain Reagent, Thermo Scientific) and exposed to a Phosphor Screen. The intensity of bands was quantified using the Molecular Dynamics STORM 840 phosphorimager and ImageQuant software. The gel was then vacuum-dried and the Coomassie staining documented.

**Protein Interaction Assays**—Co-immunoprecipitation assays were performed as described previously (6) using rabbit polyclonal antibodies against yeast eEF1A (15).

For eEF1A binding and stepwise elution assays, whole cell extract was generated as published earlier (13) using a buffer containing 30 mM HEPES, pH 7.4, 50 mM KCl, 10% glycerol, 1 complete tablet without EDTA (Roche Applied Science) per 25 ml of buffer, 5 mM β-mercaptoethanol, 5 mM imidazole, pH 7, and 1 mM PMSF. 3 mg of total protein in 400 μl of buffer was incubated with Sepharose beads for 30 min at 4 °C and spun for 1 min at 10,000 rpm at 4 °C. The supernatant was then added to Ni2+-charged iMAC resin (Bio-Rad). After incubation for 1 h at 4 °C, the resin was subjected to stepwise elutions by using buffer with increasing imidazole concentrations (ranging from 10 to 250 mM imidazole).

4 H. Qiu and A. G. Hinnebusch, unpublished data.
van’t Riet), c-myc (1:500, Roche Applied Science) or Gcn2 (1:1000). Antiserum against yeast Gcn2 (amino acids 1–633) was obtained by immunizing guinea pigs with the His-tagged protein expressed from pET28a, in *E. coli* DE3 purified by eluting from a gel slice obtained from a preparative SDS-PAGE of the insoluble cell material. The purification of the protein and immunization protocol were essentially as described previously (18). Immune complexes were visualized using horseradish peroxidase conjugated to donkey anti-rabbit antibodies (for the detection of Gcn1, eIF2α-P, RPS22 antibodies) (Pierce) goat anti-guinea pig (Gcn2) (Santa Cruz Biotechnology), or to sheep anti-mouse antibodies (RPL39) (Pierce).

RESULTS

**Gcn2 Co-elutes with His<sub>6</sub>-eEF1A, but Gcn1 Does Not**—As eEF1A accesses the ribosome during the delivery of amino acid-tRNAs to the A-site (1), as we have proposed that Gcn1 and Gcn2 detect uncharged tRNAs in the A-site during amino acid starvation (6, 9), and as eEF1A was found to also bind uncharged tRNAs (20), we wanted to investigate whether eEF1A is involved in the GAAC process. If this is the case, eEF1A should be in a complex with Gcn1 and/or Gcn2, with or without the ribosome. We reasoned that if our assumption is true, then from a strain expressing endogenously expressed His<sub>6</sub>-eEF1A as the only form of eEF1A, we should be able to co-purify Gcn1 and/or Gcn2 with His<sub>6</sub>-eEF1A. To test this, we employed a yeast strain that lacks both genes encoding eEF1A, TEF1 and TEF2, and instead expresses His<sub>6</sub>-eEF1A from a plasmid from its own promoter, either untagged or His<sub>6</sub>-tagged (TKY64 and TKY65, respectively), were grown to exponential phase and harvested. Whole cell extracts were incubated with iMAC resin, and the resins were then subsequently washed with increasing concentrations of imidazole as indicated. Equal amounts of each washing step were subjected to SDS-PAGE, and the proteins were transferred to a PVDF membrane. The membrane was probed with Ponceau S to visualize His<sub>6</sub>-eEF1A and then was subjected to immunoblotting using antibodies against Gcn1, Gcn2, and the small ribosomal protein RPS22.

FIGURE 1. **Gcn2 co-elutes with endogenously expressed His<sub>6</sub>-eEF1A.** tef1Δ/tef2Δ double deletion strains expressing eEF1A from a plasmid from its own promoter, either untagged or His<sub>6</sub>-tagged (TKY64 and TKY65, respectively), were grown to exponential phase and harvested. Whole cell extracts were generated from exponentially growing cells, and from a plasmid or untagged eEF1A as control. Whole cell extracts from a strain expressing endogenously expressed His<sub>6</sub>-eEF1A was bound to iMAC resin, and the resin was sub-
**eEF1A Binds the Gcn2 C Terminus**

**FIGURE 3. Gcn2-CTD is sufficient for forming a complex with eEF1A.** 4 and 2 μg of GST-tagged Gcn2 fragments encompassing the Gcn2 N terminus (NTD, amino acids 1–272, plasmid pB131), the protein kinase domain (PK, 568–998, pHQ531), the HisRS-like domain (HisRS, 970–1497, pHQ530), the Gcn2 C terminus (CTD, 1498–1659, pHQ531), or GST alone (pGEX-5x-1), expressed in *E. coli*, were incubated with glutathione-linked beads and purified. The immobilized fragments were then incubated with whole cell extract generated from the exponentially grown *gcn2*Δ strain H2557. Unbound proteins were removed, and the precipitate was subjected to SDS-PAGE and immunoblotting using antibodies against GST, Gcn1, eEF1A, and the ribosomal protein RPS22. The full-length GST fusion proteins are indicated with asterisks. The control fraction obtained without antibodies (Fig. 2, lanes 2 and 5 versus lane 8). By contrast, the recovery of Gcn1 was not substantially greater in the presence versus absence of eEF1A antibodies, making it unclear whether Gcn1 is specifically associated with eEF1A in WCEs. These results support the idea that Gcn2 and eEF1A reside in the same complex. Due to the affinity of eEF1A to ribosomes, it is very likely that ribosomal proteins were co-immunoprecipitated in addition to Gcn2, and thus in this assay we cannot determine whether Gcn2 binds to eEF1A directly or via the ribosome.

**Gcn2 C-terminal Domain Is Sufficient for eEF1A Interaction**—Because Gcn2 and eEF1A appear to be part of the same complex, we next identified the Gcn2 domain that mediates complex formation with eEF1A by testing various Gcn2 fragments for their ability to bind eEF1A. For this, we expressed in *E. coli* various Gcn2 fragments fused to GST. Each Gcn2 fragment was attached to glutathione-linked beads, purified, and incubated with yeast extract obtained from *gcn2*Δ strains. The precipitates were then subjected to SDS-PAGE and immunoblotting assays using antibodies against eEF1A, Gcn1, RPS22, and GST. We found that the Gcn2-CTD strongly co-precipitated eEF1A (Fig. 3), suggesting that the Gcn2 C terminus mediates complex formation with eEF1A. As published before, the Gcn2 N-terminal domain co-precipitated Gcn1 (21). The Gcn2-CTD harbors ribosome binding activity (22), and as expected it co-precipitated the ribosomal protein RPS22. Thus, although the Gcn2-CTD is sufficient for binding eEF1A in cell extracts, it was still possible that the Gcn2-eEF1A interaction is bridged by the ribosome.

**eEF1A-Gcn2 Interaction Does Not Depend on the Ribosome**—The Gcn2-CTD harbors a ribosome-binding site (22), and eEF1A is a ribosome-binding protein (1). Therefore, we next wanted to investigate whether the Gcn2-CTD-eEF1A interaction is mediated via the ribosome. It is known that in the Gcn2-CTD, the residues Lys-1552, Lys-1553, and Lys-1556 are essential for ribosome association and that K1552L, K1553I, and K1556I substitutions severely diminish Gcn2-ribosome interaction (7). If Gcn2-eEF1A interaction is mediated via the ribosome, then substitution of these Lys residues should severely impair Gcn2-eEF1A complex formation. To test this, we generated a plasmid expressing GST-Gcn2-CTD where the Lys-1552, Lys-1553, and Lys-1556 residues were replaced by Leu, Ile, and Ile, respectively (named GST-Gcn2-CTD*K). We then repeated the above in vitro co-precipitation assays. Briefly, GST-Gcn2-CTD and GST-Gcn2-CTD*K and GST alone as negative control were expressed in *E. coli* and bound to glutathione-linked resin, and unbound proteins were washed off, and the GST fusion proteins were incubated with whole cell extract derived from the *gcn2*Δ strain H2557. The precipitates were then subjected to SDS-PAGE and immunoblotting. We found that the Lys substitutions in GST-Gcn2-CTD*K reduced the CTD-mediated RPL39 and RPS22 co-precipitation by a factor of around 3, decreasing it to 37 and 29%, respectively, as compared with GST-Gcn2-CTD (Fig. 4, A and B), thus indicating that ribosome association was significantly affected as published previously (7). By contrast, the Lys substitutions reduced eEF1A co-precipitation by only ~25%, reducing it to 76% of the WT recovery. Considering that the Lys substitutions affected ribosome association of GST-Gcn2-CTD much more than its eEF1A association, this suggests that eEF1A-Gcn2 association can occur without being bridged by the ribosome. However, it is possible (even likely) that the ribosome stabilizes this interaction to some extent as both eEF1A and Gcn2 can bind independently to ribosomes.

To obtain more evidence that Gcn2-CTD-eEF1A interaction can occur independently of the ribosome, we subjected the whole cell extract (WCE) of a *gcn2*Δ strain to high velocity sedimentation to remove the ribosomes. The resulting postribosomal supernatant (PRS) and the WCE as control were subjected to SDS-PAGE and immunoblotting, and we found that in fact the ribosomal protein RPS22 was reduced to nondetectable levels in the PRS as compared with WCE, whereas the eEF1A levels were reduced by about 40% (Fig. 5A). Next we repeated the above co-precipitation assay using PRS and WCE in parallel, and we found that co-precipitation of eEF1A from the PRS was similar to that of WCE (Fig. 5B), supporting the model that Gcn2-CTD can bind eEF1A independently of the ribosome.

**Gcn2-CTD and eEF1A Directly Interact with Each Other**—To ultimately determine whether eEF1A directly binds to Gcn2, we repeated the above GST precipitation experiment but this time using only purified components. GST-Gcn2-CTD, GST-Gcn2-CTD*K, and GST alone were expressed in *E. coli* and incubated with glutathione-linked Sepharose beads as above. His<sub>6</sub>-tagged eEF1A was purified from the *gcn2*Δ strain ESY10101 with iMAC resin using high salt conditions in an effort to remove all traces of ribosomes. In fact, immunoblotting assays revealed that the ribosomal protein RPS22 was not detectable in the His<sub>6</sub>-purified preparation.
Purified His6-eEF1A was then incubated with the glutathione-linked GST-Gcn2-CTD, GST-Gcn2-CTD*K, or GST alone as control. The precipitates were subjected to SDS-PAGE and immunoblotting as described above. As observed above, GST-Gcn2-CTD as well as GST-Gcn2-CTD*K co-precipitated His6-eEF1A, and co-precipitation by GST-Gcn2-CTD*K was somewhat lower as compared with GST-Gcn2-CTD (Fig. 6C). This suggests that Gcn2-CTD-eEF1A interaction can occur without being bridged by the ribosome or another yeast protein and that the Lys residues enhance, directly or indirectly, the Gcn2-CTD-eEF1A interaction.

As both eEF1A and Gcn2-CTD have ribosome and tRNA affinity (7, 8, 22), we next tested whether this interaction is mediated by RNA. For this we repeated the above in vitro assay, except that the E. coli extract and purified His6-eEF1A were treated with RNase A just prior to mixing together these components. We found that the eEF1A co-precipitation was barely affected by RNase treatment (Fig. 6C versus D). Considering that RNA was successfully digested under these experimental conditions (Fig. 6E), our results suggest that the Gcn2-CTD-eEF1A interaction is not bridged by RNA. Together, our results strongly suggest that eEF1A directly contacts the Gcn2-CTD and that the Lys residues in this CTD are not fully required for this interaction. The Lys residues may constitute part of the eEF1A binding domain, or the Lys substitutions might alter the Gcn2-CTD structure to some extent and thereby indirectly affect Gcn2-CTD-eEF1A interaction.

Gcn2-CTD-eEF1A Interaction Is Reduced under Amino Acid Starvation—Having established that eEF1A directly contacts Gcn2, this raised the possibility that eEF1A may regulate Gcn2 function. As Gcn2 is involved in detecting and overcoming amino acid starvation, the obvious next step was to investigate whether Gcn2-CTD-eEF1A interaction changes when cells are starved for amino acids. Amino acid starvation can be elicited by adding to the medium sulfometuron, a drug causing starvation for branched-chain amino acids by inhibiting acetolactate synthase, the first common enzyme in the branched-chain amino acid biosynthetic pathway (23). To test whether Gcn2-CTD-eEF1A interaction changes when cells are starved for amino acids, we repeated the in vivo His6-eEF1A co-elution assays using cells that were treated with sulfometuron for 30 min before harvesting. We found that under starvation conditions the co-elution of the ribosomal protein RPS22 was diminished (Fig. 7). This was expected as under starvation conditions...
protein synthesis is down-regulated. Interestingly, under starvation conditions Gcn2 did not co-elute with eEF1A as found under replete conditions (Fig. 7), suggesting that Gcn2-eEF1A interaction is impaired under starvation conditions. This change in interaction raises the possibility that eEF1A is a negative regulator of Gcn2 function in amino acid-replete conditions.

Considering that eEF1A contacts the Gcn2-CTD, which binds the starvation signal uncharged tRNAs, and that under starvation eEF1A-Gcn2 interaction is lost, this prompted us to investigate whether uncharged tRNAs diminish eEF1A-Gcn2 interaction. To test this, we conducted in vitro eEF1A-Gcn2 binding assays using purified His$_{6}$-tagged eEF1A and purified Gcn2. Gcn2 was incubated with various amounts of uncharged tRNA$^{\text{Phe}}$. As control, Gcn2 was incubated with no tRNA or with Gcn2 kinase function of unknown identity.

**eEF1A Inhibits Gcn2-mediated eIF2α Phosphorylation in Vitro**—To test whether eEF1A is a negative regulator of Gcn2, we investigated whether purified eEF1A can inhibit Gcn2 function in vitro. Gcn2 kinase function can be easily scored via its autophosphorylation and eIF2α phosphorylation activities in the presence of radioactively labeled ATP. For this assay, Gcn2 and untagged eEF1A were purified from yeast, and a recombinant form of yeast eIF2α (12) was expressed and purified from E. coli. Gcn2 was incubated with eEF1A, and then eIF2α and [γ-$^{32}$P]ATP were added to the assay. The samples were resolved via SDS-PAGE, and the gel was subjected to autoradiography to determine which proteins were phosphorylated and to what extent. In control kinase assays, we first investigated Gcn2 and eEF1A individually. As expected, Gcn2 underwent autoposphorylation, and it phosphorylated eIF2α (Fig. 8A, lane 1). In the absence of Gcn2, the eEF1A sample did not confer phosphorylation of eIF2α (Fig. 8A, lane 2), confirming that the eEF1A sample is devoid of Gcn2. We observed that in the eEF1A sample two proteins with the sizes of 40 and 10 kDa were phosphorylated (Fig. 8A, bands labeled with 40 kDa? and 40 kDa?), suggesting that the eEF1A sample contains traces of a kinase of unknown identity.

When Gcn2 was preincubated with eEF1A, the amount of Gcn2-mediated eIF2α phosphorylation was reduced; however, the level of Gcn2 autophosphorylation was not affected (Fig. 7, lane 1 versus 3). When repeating the assay with three different amounts of eEF1A, we found that increasing amounts of eEF1A conferred increasing reductions in eIF2α phosphorylation, although Gcn2 autophosphorylation again was not affected (Fig. 8B, lane 1 versus lanes 2–4, and C), supporting the idea that eEF1A inhibits Gcn2 function in substrate phosphorylation. Addition of increasing amounts of eEF1A simultaneously increased the phosphorylation levels of the 40- and 10-kDa proteins, however, this was not the reason for the decrease in eIF2α phosphorylation e.g. due to depletion of the ATP pool, because the level of Gcn2 autophosphorylation remained unaffected.

To obtain more evidence that Gcn2 mediated eIF2α phosphorylation is impaired by eEF1A and not by a contamination in the eEF1A sample, we repeated the kinase assay using His$_{6}$-tagged eEF1A from Fig. 6 that was purified via a procedure different to that used for purifying untagged eEF1A. As found
for native eEF1A, increasing amounts of His6-eEF1A provoked an obvious reduction in eIF2α/H9251 phosphorylation, and heat inactivation of His6-eEF1A prior to the kinase assay completely reverted this effect (Fig. 8D). Comparable aliquots of a mock affinity purification from an isogenic yeast strain expressing untagged eEF1A showed no inhibitory activity (data not shown). Except for phosphorylated Gcn2 and eIF2α, no extra bands were observed in the autoradiogram in the presence of His6-eEF1A, suggesting that His6-eEF1A did not contain traces of the unknown kinase found in the native eEF1A sample. In case of His6-eEF1A, the decrease in eIF2α phosphorylation correlated with an increase in Gcn2 phosphorylation, indicating again that the reduction of eIF2α phosphorylation was not due to the depletion of the ATP pool or a nonspecific kinase inhibitor.

Finally, we confirmed that our kinase assay is linear under the conditions where eEF1A inhibition of Gcn2 is observed. For this we conducted kinase assays with various incubation times, in the presence and absence of eEF1A, and we determined the amount of co-precipitated Gcn2 and eIF2α relative to their phosphorylation levels under standard kinase assay conditions, i.e. 20-min reaction time in the absence of eEF1A. From the data in Fig. 8E, it can be clearly seen that for the standard kinase incubation time of 20 min used in our assays, the enzyme reaction was still linear, in the presence and absence of eEF1A.

The fact that Gcn2 autophosphorylation did not decrease in the presence of eEF1A in contrast to eIF2α phosphorylation (see bar graphs in Fig. 8C and D) suggests that the Gcn2 inhibition is specific and not due to a toxic compound that unspecifically impairs Gcn2 kinase activity.

Together, our findings are in agreement with the idea that eEF1A functions as a negative regulator of Gcn2 by specifically inhibiting Gcn2-mediated eIF2α phosphorylation without blocking Gcn2 autophosphorylation.

**DISCUSSION**

Constant protein synthesis is paramount to life as is a constant supply of amino acid substrates for this process. It is thought that, in addition to protein synthesis, monitoring
amino acid availability also occurs on ribosomes (1, 6, 7, 9, 22, 24). eEF1A delivers aminoacyl tRNAs to the ribosomal A-site, and studies suggest that starvation is monitored in the A-site by a large complex containing Gcn1 and Gcn2 (1, 6, 9). This prompted us to investigate whether eEF1A may contact Gcn1 or Gcn2 and might be involved in the GAAC system.

In this work, we have provided several lines of evidence that Gcn2 resides in a complex with eEF1A. eEF1A antibodies co-immunoprecipitated Gcn2 from yeast whole cell extract. Fur-
eEF1A Binds the Gcn2 C Terminus

thermore, in eEF1A binding and stepwise elution assays, Gcn2 co-purified with eEF1A from yeast whole cell extracts. The Gcn1 elution profile did not completely match but did partially overlap with that of Gcn2 and eEF1A. This raised the possibility that Gcn1 is associated with the eEF1A-Gcn2 complex but is not an integral component of it.

We have provided strong evidence that Gcn2 and eEF1A interact with each other via the Gcn2-CTD. Using Gcn2 fragments fused to GST in glutathione-mediated pulldown assays, we found that the Gcn2-CTD was sufficient for co-precipitating eEF1A. (As our fragments did not cover Gcn2 amino acids 273–567, we cannot exclude the possibility that Gcn2 harbors a second eEF1A binding activity in its N terminus.) The Gcn2-CTD has ribosome binding activity and contributes to the binding of uncharged tRNAs (8, 25); however, we found that the removal of ribosomes from cell extracts via high speed centrifugation had a very minor effect on Gcn2-eEF1A interaction (Fig. 5B). Furthermore, purified eEF1A bound to purified Gcn2-CTD (Fig. 6C, lane 2), and RNase A treatment to remove any traces of RNA had no detectable effect on the efficiency of this interaction (Fig. 6, C, lane 2, versus D, lane 5). Thus, our findings suggest that Gcn2 and eEF1A directly interact with each other via the Gcn2-CTD.

Lysine residues 1552, 1553, and 1556 in the Gcn2-CTD have been shown previously to be required for ribosome binding and tRNA binding, and substitution of these Lys residues by hydrophobic amino acids severely affects ribosome and tRNA association (7, 8). Substitution of these Lys residues, in Gcn2-CTD*K, did affect the eEF1A-Gcn2 interaction to some extent both in vivo and in vitro (Figs. 4 and 6C). However, as the Lys substitutions affected Gcn2-CTD-ribosome association more than the Gcn2-CTD-eEF1A association in vivo (Fig. 4B), this finding is still in agreement with the idea that Gcn2-eEF1A interaction is not bridged by the ribosome. Furthermore, the fact that purified Gcn2-CTD co-precipitated purified eEF1A that is devoid of detectable ribosomes, following RNase treatment, and even when the Gcn2-CTD Lys residues were substituted by hydrophobic amino acids (Fig. 6), strongly suggests that the Gcn2-CTD is sufficient for a direct interaction with eEF1A. It is possible that the Lys residues constitute part of the eEF1A-binding site (see below) or the amino acid substitutions changed the Gcn2-CTD structure in a way that indirectly affects Gcn2-eEF1A binding.

Direct physical interaction strongly suggests that eEF1A provides a cross-talk between protein synthesis and GAAC and/or that eEF1A is involved in GAAC. Supporting this idea, we found that in vivo Gcn2-eEF1A interaction occurs under amino acid-replete conditions but not under starvation conditions (Fig. 7), suggesting that eEF1A may be involved in keeping Gcn2 in its latent state when amino acids are plentiful. If eEF1A is a Gcn2 inhibitor, then overexpression of eEF1A should impair Gcn2 activation under amino acid starvation conditions; however, this test was not possible because eEF1A overexpression is known to be highly deleterious to the cell due to the multifaceted functions eEF1A (26). Instead, we asked whether Gcn2 activation is inhibited in the presence of eEF1A by employing an in vitro kinase assay using only purified proteins. Interestingly, we found that Gcn2 phosphorylated its substrate eIF2α with lower efficiency when eEF1A was present, and this inhibition increased with the amount of eEF1A present in the assay. It seems unlikely that an unknown component in the eEF1A sample inhibited Gcn2 unspecifically, because eEF1A proteins obtained via two different purification procedures showed the same effect on eIF2α phosphorylation, and because Gcn2 autophosphorylation was not affected in the same way as eIF2α phosphorylation. Lack of an effect on autophosphorylation, or in the case of His6-eEF1A an increase in Gcn2 phosphorylation, also ensured that ATP was not a limiting factor in our assays. Taken together, our findings are all in agreement with the idea that eEF1A inhibits Gcn2 activity in phosphorylating its substrate eIF2α.

It is intriguing that eEF1A inhibited only eIF2α phosphorylation but not Gcn2 autophosphorylation. The ability of Gcn2 to autophosphorylate is indicative of the kinase domain being functional. But why did it not phosphorylate eIF2α? Gcn2 resides in the cell in an inactive state due to intramolecular autoinhibitory interactions; in particular there is evidence that contact between the CTD and protein kinase domain prevents Gcn2 activation (27, 28). Moreover, the crystal structure of the Gcn2 kinase domain revealed a closed conformation that restricts ATP binding and displays a nonproductive orientation of helix αC (28, 29). Under amino acid starvation, the HisRS-like domain binds uncharged tRNA, and this leads to an allosteric stimulation of the kinase domain, which evokes autophosphorylation of the Gcn2 kinase domain (8, 27–29). It is possible that autophosphorylation leads to further intramolecular re-arrangements in Gcn2 necessary for eIF2α recognition and subsequent phosphorylation of Ser-51. Indeed, evidence for this mechanism has been reported for the human eIF2α kinase PKR (30, 31). If so, eEF1A could impede this rearrangement in Gcn2 as one way of inhibiting substrate phosphorylation. An equally plausible model is suggested by the distinctive mechanism of

FIGURE 8. eEF1A inhibits Gcn2-mediated eIF2α phosphorylation but not Gcn2 auto-phosphorylation. A, 1 pmol of purified Gcn2 and/or 10 pmol of purified untagged eEF1A as indicated at 30 °C in the presence of BSA before being subjected to a second incubation with 30 pmol of recombinant eIF2α and 100 pmol of [γ-32P]ATP for 20 min. Samples were then subjected to SDS-PAGE; the gel was subjected to Coomassie staining and autoradiography (right panel), and then the gel was dried and the Coomassie staining documented (left panel). The location of protein bands of Gcn2, BSA, eEF1A, and eIF2α (a C-terminally truncated version of yeast eIF2α) are indicated, as well as 40- and 10-kDa bands observed in the autoradiogram. A second independent experiment showed similar results. B, same assay was conducted as in A, lane 3, just that 200 pmol of [γ-32P]ATP was used and various amounts of eEF1A (1, 5, and 10 pmol). C, levels of Gcn2 auto-phosphorylation (Gcn2-P), eIF2α phosphorylation (eIF2α-P), and phosphorylation of the 10-kDa protein (10 kDa-P), in A and B, were determined by quantifying the intensity of the respective bands. The values were normalized to that of Gcn2 in the absence of eEF1A (for Gcn2-P and eIF2α-P) and to that of eEF1A in the absence of Gcn2 (for 10 kDa-P). Data were obtained from 4, 2, 1, 2, and 1 experiments (columns from left to right), and standard errors are indicated where applicable. D, same assay as in B was conducted but using 0, 1, 5, 10, and 50 pmol of His6-tagged eEF1A from Fig. 6. If indicated eEF1A was heat-inactivated prior to the enzyme assay (10 min at 95 °C). The levels of Gcn2 auto-phosphorylation (Gcn2-P) and eIF2α phosphorylation (eIF2α-P) were determined as outlined in C, E, same assay as in D was conducted using 10 pmol of His6-eEF1A, just that the kinase reaction was terminated after various times, i.e. S, 10, 20, and 40 min. The levels of Gcn2 auto-phosphorylation (Gcn2-P) and eIF2α phosphorylation (eIF2α-P) were determined as outlined in C, relative to the phosphorylation level after 20 min of kinase reaction and in the absence of eEF1A and plotted in a line graph.
substrate recognition employed by eIF2α kinases PKR and Gcn2, involving critical interaction of an epitope in eIF2α remote from Ser-51 with helix eG in the C-terminal lobe of the kinase domain (28, 30, 31). eEF1A might interfere with this “docking” interaction that is crucial for substrate phosphorylation but dispensable for autophosphorylation.

Interestingly, in vitro eEF1A-Gcn2 interaction was modulated by uncharged tRNAs. eEF1A co-precipitated Gcn2 less efficiently in the presence of uncharged tRNAs. This raises the intriguing possibility that under starvation conditions the starvation signal removes eEF1A from Gcn2 to allow Gcn2 activation. We were unable to demonstrate in vitro that uncharged tRNAs reverted the inhibitory effect of eEF1A on Gcn2-mediated eIF2α phosphorylation (data not shown). However, this is not surprising considering that so far nobody has managed to reconstitute in vitro activation of yeast Gcn2 by tRNA. This may be due to the fact that Gcn2 activation is more complicated than anticipated and that additional not-yet-identified factors are important for tRNA-mediated Gcn2 activation.

Based on our results we propose the following hypothetical model for eEF1A-mediated Gcn2 inhibition. Under amino acid-replete conditions, the cellular level of uncharged tRNAs is low; however, Gcn2 might still get activated occasionally by the basal level of uncharged tRNAs. Under these conditions, eEF1A binding to Gcn2 would impede eIF2α phosphorylation by the autophosphorylated form of Gcn2 (Fig. 9). Considering that yeast cells contain about 5,000–6,000-fold higher levels of eIF1A molecules than Gcn2 molecules (calculated from Refs. 32, 33), one can envision that eEF1A inhibits Gcn2 very efficiently. Under starved conditions, the cellular level of uncharged tRNAs increases, and these are sensed by the Gcn2 HisRS-like domain (Fig. 9) (2). Gcn2 becomes activated with attendant autophosphorylation, and eEF1A dissociates from the Gcn2-CTD to allow eIF2α phosphorylation (Fig. 9). The mechanism leading to eEF1A-Gcn2 dissociation remains to be determined; however, based on our results it is tempting to consider that competition between uncharged tRNA and eEF1A for interaction with the Lys residues in the Gcn2-CTD could be a contributing factor.

Taken together, our studies provide evidence for a new mechanism of regulating Gcn2 that involves a factor of the protein synthesis machinery, eEF1A. The key role for Gcn2 in regulating protein synthesis and many additional key processes in higher eukaryotes, such as memory formation and the immune system (34, 35), together with protein synthesis being central to life, underscore the importance of further elucidating the connections between translation elongation factors and GAAC. Interestingly, eEF1A has been linked to many diseases, including cancer (36, 37), and Gcn2 has been implicated in the cell cycle (38). Furthermore, eEF1A is known to have many additional functions outside of protein synthesis, such as regulating the actin cytoskeleton, apoptosis, and protein degradation (26), raising the intriguing possibility that eEF1A may be involved in fine-tuning Gcn2 activity to various cellular conditions. Supporting this idea, Gcn2 has been linked to apoptosis and the proteasome (39) and to the actin cytoskeleton via its regulator Yih1 (11, 40). Thus, further studies on the eEF1A-Gcn2 connection are paramount to fully understand the intricacies of Gcn2 regulation.

Acknowledgments—We are grateful to Kristina Blagoeva and Tracey Waller for technical support, Jan van’t Riet and Maurice Swanson for antibodies, and Hongfang Qiu for plasmids.

REFERENCES

1. Taylor, D. R., Frank, J., and Kinzy, T. G. (eds) (2007) Translational Control in Biology and Medicine (Mathews, M. B., Sonenberg, N., and Hershey, J. W. B., eds) Monograph Series 48, pp. 59–85, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
2. Hinnebusch, A. G. (2005) Annu. Rev. Microbiol. 59, 407–450
3. Sattlegger, E., Hinnebusch, A. G., and Barthelmes, I. B. (1998) J. Biol. Chem. 273, 20404–20416
4. Sasse, C., Bignell, E. M., Hasenberg, M., Haynes, K., Gunzer, M., Braus, G. H., and Krappmann, S. (2008) Fungal Genet. Biol. 45, 693–704
5. Hood, H. M., Neafsey, D. E., Galagan, J., and Sachs, M. S. (2009) Annu. Rev. Microbiol. 63, 385–409
6. Sattlegger, E., and Hinnebusch, A. G. (2000) EMBO J. 19, 6622–6633
7. Zhu, S., and Wek, R. C. (1998) J. Biol. Chem. 273, 1808–1814
8. Dong, J., Qiu, H., Garcia-Barrio, M., Anderson, J., and Hinnebusch, A. G. (2000) Mol. Cell 6, 269–279
9. Marton, M. J., Vazquez de Aldana, C. R., Qiu, H., Chakrabortty, K., and Hinnebusch, A. G. (1997) Mol. Cell. Biol. 17, 4474–4489
10. Marchie, M. J., and Leader, D. P. (1978) Biochim. Biophys. Acta 520, 233–236
11. Sattlegger, E., Swanson, M. J., Ashcraft, E. A., Jennings, J. L., Fekete, R. A., Link, A. J., and Hinnebusch, A. G. (2004) J. Biol. Chem. 279, 29952–29962
12. Zhu, S., Sobolev, A. Y., and Wek, R. C. (1996) J. Biol. Chem. 271, 24989–24994
13. Visweswaraih, J., Daulet, M., and Sattlegger, E. (2011) Nat. Protoc. Exchange doi:10.1038/protex.2011.212
14. Pittman, Y. R., Kandil, K., Lewis, M., Valente, L., and Kinzy, T. G. (2009) J. Biol. Chem. 284, 4739–4747
15. Carr-Schmid, A., Durko, N., Cavallius, J., Merrick, W. C., and Kinzy, T. G. (1999) J. Biol. Chem. 274, 30297–30302
16. Sambrook, J. F., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, p. 18.67, Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, NY

17. Vazquez de Aldana, C. R., Marton, M. J., and Hinnebusch, A. G. (1995) EMBO J. 14, 3184–3199
18. Bittencourt, S., Pereira, C. M., Avedissian, M., Delamano, A., Mello, L. E., and Castilho, B. A. (2008) J. Comp. Neurol. 507, 1811–1830
19. Anderson, J. T., Paddy, M. R., and Swanson, M. S. (1993) Mol. Cell. Biol. 13, 6102–6113
20. Petrushenko, Z. M., Negrutskii, B. S., Ladokhin, A. S., Budkevich, T. V., Shalak, V. F., and El’skaya, A. V. (1997) FEBS Lett. 407, 13–17
21. Garcia-Barrio, M., Dong, J., Ufano, S., and Hinnebusch, A. G. (2000) EMBO J. 19, 1887–1899
22. Ramirez, M., Wek, R. C., and Hinnebusch, A. G. (1991) Mol. Cell. Biol. 11, 3027–3036
23. LaRossa, R. A., and Schloss, J. V. (1984) J. Biol. Chem. 259, 8753–8757
24. Sattlegger, E., and Hinnebusch, A. G. (2005) J. Biol. Chem. 280, 16514–16521
25. Ramirez, M., Wek, R. C., Vazquez de Aldana, C. R., Jackson, B. M., Freeman, B., and Hinnebusch, A. G. (1992) Mol. Cell. Biol. 12, 5801–5815
26. Mateyk, M. K., and Kinzy, T. G. (2010) J. Biol. Chem. 285, 21209–21213
27. Qiu, H., Jiang, H. Y., and Anthony, T. G. (2006) Biochem. Soc. Trans. 34, 7–11
28. Sattlegger, E., Barbosa, J. A., Moraes, M. C., Martins, R. M., Hinnebusch, A. G., and Castilho, B. A. (2011) J. Biol. Chem. 286, 10341–10355
29. Dar, A. C., Dever, T. E., and Sicheri, F. (2005) Cell 122, 887–900
30. Dey, M., Cao, C., Dar, A. C., Tamura, T., Ozato, K., Sicheri, F., and Dever, T. E. (2005) Cell 122, 901–913
31. Condeelis, J. (1995) Trends Biochem. Sci. 20, 169–170
32. Ghaemmaghami, S., Huh, W. K., Bower, K., Howson, R. W., Belle, A., Dephoure, N., O’Shea, E. K., and Weissman, J. S. (2003) Nature 425, 737–741
33. Costa-Mattioli, M., Gobert, D., Harding, H., Herdy, B., Azzi, M., Bruno, M., Bidinosti, M., Ben Mamou, C., Marcinkiewicz, E., Yoshida, M., Imataka, H., Cuello, A. C., Seidah, N., Sossin, W., Lacaille, J. C., Ron, D., Nader, K., and Sonenberg, N. (2005) Nature 436, 1166–1173
34. Fallarino, F., Grohmann, U., You, S., McGrath, B. C., Cavener, D. R., Vacca, C., Orabona, C., Bianchi, R., Belladonna, M. L., Volpi, C., Santamaria, P., Fioretti, M. C., and Puccetti, P. (2006) J. Immunol. 176, 6752–6761
35. Lamberti, A., Caraglia, M., Longo, O., Marra, M., Abbruzzese, A., and Arcari, P. (2004) Amino Acids 26, 443–448
36. Van Goietsenoven, G., Hutton, J., Becker, J. P., Lallemant, B., Robert, F., Lefranc, F., Pirker, C., Vandenbussche, G., Van Antwerpen, P., Evidente, A., Berger, W., Prévost, M., Pelletier, J., Kiss, R., Kinzy, T. G., Kornienko, A., and Mathieu, V. (2010) FASEB J. 24, 4575–4584
37. Grallert, B., and Boye, E. (2007) Cell Cycle 6, 2768–2772
38. Foiani, M., Cigan, A. M., Paddon, C. J., Harashima, S., and Hinnebusch, A. G. (1991) Mol. Cell. Biol. 11, 3203–3216
39. Dey, M., Cao, C., Dar, A. C., Tamura, T., Ozato, K., Sicheri, F., and Dever, T. E. (2005) Cell 122, 887–900
40. Foiani, M., Cigan, A. M., Paddon, C. J., Harashima, S., and Hinnebusch, A. G. (1991) Mol. Cell. Biol. 11, 3203–3216
41. Cigan, A. M., Paddon, C. J., Harashima, S., and Hinnebusch, A. G. (1995) Mol. Cell. Biol. 15, 2697–2711